San Francisco-Testis-sparing approaches are appropriate for many prepubertaltestis tumors, according to two decades of data from a tumor registry setup by the American Academy of Pediatrics Section on Urology. The registry,established in 1980, has enrolled 395 boys with primary testis tumors thatpresented before 12 years of age.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.